Literature DB >> 23242327

The effect of the order of total body irradiation and chemotherapy on graft-versus-host disease.

Motohiro Kato1, Ryosuke Shiozawa, Katsuyoshi Koh, Yoshihisa Nagatoshi, Junko Takita, Kohmei Ida, Akira Kikuchi, Ryoji Hanada.   

Abstract

BACKGROUND: Graft-versus-host disease (GVHD) is one of the most important complications in allogeneic hematopoietic stem cell transplantation. Intensity of conditioning regimen is one of the risk factors, which is associated with acute GVHD, and some studies have shown that alteration of the administration order from busulfan to cyclophosphamide to cyclophosphamide to busulfan could decrease cytokine levels and organ toxicity.
METHODS: To investigate whether the order of total body irradiation (TBI) and chemotherapy is associated with the incidence of GVHD, we reviewed the charts of 124 consecutive hematopoietic stem cell transplantation, which was performed in Saitama Children's Medical Centre and University of Tokyo Hospital between 1995 and 2010.
RESULTS: TBI performed before chemotherapy (TBI-CT) showed an increased risk for grades II to IV acute GVHD (61.6±7.8%) compared with the TBI performed after chemotherapy (CT-TBI) (42.8±7.2%) (P=0.048), whereas the incidence of grades III and IV GVHD were similar between TBI-CT and CT-TBI. Multivariate analysis showed that TBI-CT was associated with a higher risk of grades II to IV acute GVHD. However, overall survival probability of TBI-CT cohort was similar to that of CT-TBI cohort.
CONCLUSIONS: Our results provided a novel risk factor for acute GVHD, which can be easily controlled by the physician.

Entities:  

Mesh:

Year:  2014        PMID: 23242327     DOI: 10.1097/MPH.0b013e318279e81c

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  1 in total

1.  Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation.

Authors:  K Motohashi; S Fujisawa; M Onizuka; S Kako; E Sakaida; K Shono; R Tatara; N Doki; T Mori; T Sakura; N Aotsuka; E Fuji; N Tomita; N Kawai; T Saitoh; K Usuki; J Taguchi; R Watanabe; S Kobayashi; S Yano; H Kanamori; S Takahashi; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.